1. Home
  2. PLRX vs OLP Comparison

PLRX vs OLP Comparison

Compare PLRX & OLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLRX
  • OLP
  • Stock Information
  • Founded
  • PLRX 2015
  • OLP 1982
  • Country
  • PLRX United States
  • OLP United States
  • Employees
  • PLRX N/A
  • OLP N/A
  • Industry
  • PLRX Biotechnology: Pharmaceutical Preparations
  • OLP Real Estate Investment Trusts
  • Sector
  • PLRX Health Care
  • OLP Real Estate
  • Exchange
  • PLRX Nasdaq
  • OLP Nasdaq
  • Market Cap
  • PLRX 641.5M
  • OLP N/A
  • IPO Year
  • PLRX 2020
  • OLP N/A
  • Fundamental
  • Price
  • PLRX $11.21
  • OLP $25.76
  • Analyst Decision
  • PLRX Strong Buy
  • OLP Strong Buy
  • Analyst Count
  • PLRX 7
  • OLP 1
  • Target Price
  • PLRX $40.50
  • OLP $28.00
  • AVG Volume (30 Days)
  • PLRX 560.2K
  • OLP 65.7K
  • Earning Date
  • PLRX 02-26-2025
  • OLP 03-04-2025
  • Dividend Yield
  • PLRX N/A
  • OLP 7.03%
  • EPS Growth
  • PLRX N/A
  • OLP 51.11
  • EPS
  • PLRX N/A
  • OLP 1.63
  • Revenue
  • PLRX N/A
  • OLP $89,142,000.00
  • Revenue This Year
  • PLRX N/A
  • OLP N/A
  • Revenue Next Year
  • PLRX N/A
  • OLP $4.71
  • P/E Ratio
  • PLRX N/A
  • OLP $15.81
  • Revenue Growth
  • PLRX N/A
  • OLP N/A
  • 52 Week Low
  • PLRX $10.22
  • OLP $19.25
  • 52 Week High
  • PLRX $18.92
  • OLP $30.45
  • Technical
  • Relative Strength Index (RSI)
  • PLRX 37.19
  • OLP 37.32
  • Support Level
  • PLRX $11.02
  • OLP $24.82
  • Resistance Level
  • PLRX $12.70
  • OLP $27.64
  • Average True Range (ATR)
  • PLRX 0.80
  • OLP 0.60
  • MACD
  • PLRX -0.18
  • OLP -0.04
  • Stochastic Oscillator
  • PLRX 8.21
  • OLP 33.33

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Share on Social Networks: